Skip to main navigation Skip to search Skip to main content

Daunorubicin efflux assay in determining multidrug resistance of patients with acute myeloid leukemia

  • Dong Hwan Kim
  • , Nan Young Lee
  • , Jong Gwang Kim
  • , Sang Kyun Sohn
  • , Dong Il Won
  • , Jang Soo Suh
  • , Gun Soo Lee
  • , Shung Chull Chae
  • , Kyu Bo Lee
  • Kyungpook National University

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

We evaluated the predictive value of mdr1 mRNA RT-PCR, P-glycoprotein (Pgp), and Daunorubicin efflux assays as regards achieving complete remission (CR), overall survival (OS), and leukemia-free survival (LFS) in 72 patients with AML. mdr1 mRNA, Pgp, and Efflux were expressed in 55.6%, 36.1%, and 33.3%. Efflux+ was associated with a lower CR rate (P=0.006). A multivariate analysis of OS identified 3 prognostic factors: WBC (P=0.028), age (P=0.002), and Efflux (P=0.005), while those of LFS identified 2 prognostic factors: age (P=0.021) and Efflux (P < 0.001). Efflux was the most reliable method in predicting an achievement of CR and stratifying the patients according to the prognosis in terms of OS and LFS in AML.

Original languageEnglish
Pages (from-to)63-70
Number of pages8
JournalLeukemia and Lymphoma
Volume46
Issue number1
DOIs
StatePublished - Jan 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Acute myeloid leukemia
  • Cytogenetics
  • Daunorubicin efflux assay
  • Multidrug resistance

Fingerprint

Dive into the research topics of 'Daunorubicin efflux assay in determining multidrug resistance of patients with acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this